Order book momentum puts Q1 execution in focus for India's solar-to-modules player
After a 111% revenue surge in FY26, Saatvik enters Q1 with ₹380+ crores in fresh orders and a critical test: can the subsidiary's solar module manufacturing keep pace with top-line growth while sustaining margins?
The Setup: From Growth to Execution
Saatvik Green Energy reported a 111% revenue surge to ₹45,484 crores in FY-2026, powered by 3,162 MW of solar generation capacity at 84.07% utilization. The company's strategy pivoted from pure EPC (engineering-procurement-construction) to in-house solar module manufacturing via subsidiary Saatvik Solar Industries—a margin-accretive moat. Now Q1 FY-2027 will test whether this momentum holds and, crucially, whether the subsidiaries can scale production to fulfill the ₹380+ crores in fresh orders booked since April 2026 without eroding margins.
The trading window closed on June 26 ahead of the August 14 board meeting, signaling a structured communication plan for Q1 results. Notably, subsidiaries Saatvik Cleantech EPC and Saatvik Solar Industries issued corporate guarantees for ₹197 crores in loans (filed July 31)—a sign the group is aggressively funding capex to meet order timelines. Meanwhile, the April 2026 acquisition of 80% of Melcon Transformers (₹24 crores) suggests vertical integration into transformer manufacturing, potentially to reduce input costs or serve EPC projects in-house.
~₹11,000–12,500 Cr annualized
Pace from FY26's ₹45,484 Cr; Q1 seasonality may soften vs Q4, but order book visibility is high
₹380+ Cr fresh orders
April–July: ₹71.25 Cr + ₹171.45 Cr + ₹138 Cr; execution timelines critical (Oct 2026 target on largest)
Watch the rate
FY26 hit 84.07%; can subsidiary production ramp keep pace with order intake without bottlenecks?
Key swing factor
Module manufacturing should improve blended margins vs pure EPC; watch for input cost inflation (polysilicon, glass, frames) and pricing power
What On-Plan Looks Like
A strong Q1 print would show: (1) revenue on trajectory for annualized ₹50,000+ crores (extending FY26 growth into FY27), (2) gross margins stable or expanding YoY due to higher-margin module manufacturing mix, (3) subsidiary revenue contribution climbing as orders execute (especially the ₹171.45 Cr order with Oct 2026 deadline), (4) capacity utilization maintained at 80%+, and (5) management confidence that ₹197 Cr capex is on schedule to support order fulfillment by target dates.
A weak Q1 print would be marked by: (1) revenue stalling or declining QoQ (suggesting order delays or seasonality worse than expected), (2) margin compression despite higher module volumes (indicating input cost inflation not passed through pricing), (3) subsidiary revenue tracking below expectations or profitability lagging parent, (4) capacity utilization falling below 75% (signaling demand or execution problems), or (5) any disclosure of order deferrals, execution delays, or capex overruns that threaten timeline targets.
On Track with Full-Year Momentum?
Saatvik has not issued formal FY-2027 guidance, but the order book and capex signals point to aggressive growth targets. The ₹197 Cr subsidiary loan guarantees (July 31) suggest management is funding for significant capex, likely to ramp solar module production. The largest order—₹171.45 crores with October 2026 execution—is due within Q2-Q3, creating a meaningful revenue milestone. If Q1 shows strong order execution pace and subsidiary contribution tracking materially, confidence will climb for hitting or exceeding FY26's ₹45,484 Cr run-rate. Conversely, any signals of timeline slippage or input cost pressure will invite downgrades.
Street View: Coverage & Consensus
Since Last Quarter: Key Filings & Corporate Actions
1 · Large Order Inflow & Execution Timeline Risk
May 26: ₹171.45 Cr order from an IPP/EPC player, due October 2026. July 22: ₹138 Cr order for solar modules from Saatvik Solar Industries. April 21: ₹71.25 Cr order. Watch: Are these orders executing on schedule? Are there any cost overruns or delivery deferrals being disclosed?
2 · Aggressive Capex & Subsidiary Loan Guarantees
July 31: Subsidiaries issued ₹197 Cr in corporate guarantees for loans—substantial funding to ramp production. Monitor: Are these facilities operational? Is capex tracking budget? Any cost inflation or timeline slippage?
3 · Vertical Integration via Melcon Transformers Acquisition
April 23: Saatvik acquired 80% of Melcon Transformers & Electricals Private Limited for ₹24 crores. This move suggests in-house transformer manufacturing to support EPC projects and reduce input costs. Q1 earnings should comment on integration progress and margin contribution.
4 · Insider Trading Window & Regulatory Monitoring
June 26: Insider trading window closed for directors and KMPs. May 13: CRISIL monitoring report for IPO proceeds utilization filed (Q4 FY26). No unusual insider activity or regulatory red flags reported.
5 · Ownership & Promoter Confidence
Promoter stake steady at 75.99%; DII uptick from 9.35% (Q3) to 10.97% (Q1 FY27) signals institutional confidence. FII minimal (0.19%) but growing from near-zero. Stock down 24% from ATH; oversold on sentiment rather than fundamentals.
What to Watch on Result Day
1 · Revenue run-rate and order execution pace
Is topline tracking FY26's trajectory (₹45,484 Cr annual run-rate) or accelerating further? How much Q1 revenue is attributable to recent order fulfillment (₹380+ Cr book)? Any delays or deferrals to disclose?
2 · Subsidiary margin contribution & capacity ramp
What % of revenue is from Saatvik Solar Industries (module manufacturing) vs parent EPC? Are blended gross margins expanding YoY? Is capacity utilization sustaining or dipping?
3 · Capex spend and ₹197 Cr loan utilization
How much of the ₹197 Cr subsidiary guarantees have been drawn? Are capex projects on track? Any cost overruns or timeline slippage on the major orders (especially the ₹171.45 Cr October deadline)?
4 · Input cost inflation and pricing power
Polysilicon, glass, and aluminum prices are key drivers of module margins. Has Saatvik been able to pass through cost increases to customers, or is margin compression visible? Management guidance on sourcing and hedging?
5 · FY-2027 guidance and capital allocation
Does management provide full-year revenue, EBITDA, or margin targets? Dividend or capital return plans? Any M&A pipeline updates (beyond Melcon integration)?
Saatvik Green Energy enters Q1 FY-2027 as a pure-play renewable EPC and module manufacturing story in a buoyant green energy market. The ₹380+ crores in fresh orders and aggressive capex (₹197 Cr subsidiary guarantees) signal conviction in demand and margin expansion. August 14's results will reveal whether execution is matching ambition: the litmus tests are Q1 revenue pace, subsidiary margin contribution, and confidence in meeting major order timelines (especially the ₹171.45 Cr October 2026 deadline). With FII ownership minimal but DII climbing and the stock off its highs, a strong execution print could reignite institutional flows. Watch for any signals of input cost pressure, order delays, or capex overruns—these would invite downgrades in a thin-coverage name.
Order book solid; execution crumbles
A ₹8,200-crore order book masks execution collapse: Q1 sales tumbled 42%, PAT crashed to ₹5.4 crore (1% margin), and management's 'selective execution' claim doesn't square with the numbers. Cell ramp in Q3 is the only redemption path — but timing and delivery are binary risks.
₹5.4 Cr
1% margin; prior year ₹116 Cr (1.3%)
334 MW
-42% YoY; vs 579 MW Q1 FY26
6.35 GW
₹8.2K Cr, 12–18 mo execution
₹6,000 Cr
Implies 875–1,000 MW avg/qtr; Q1 shortfall ~66%
Saatvik's Q1 result is a portrait of visible long-term strength masking acute near-term execution risk. A ₹8,200-crore order book (6.35 GW, up 8% year-on-year) sits alongside order book equivalent to 132% of current module capacity — textbook forward visibility. Yet Q1 delivered just 334 MW in sales (down 42% year-on-year) and ₹5.4 crore in net profit (down 96% year-on-year, just 1% margin). The street saw through it immediately: day-1 reaction was -5.79%, and the stock sits 27% below its all-time high, below all three moving averages.
The gap between orderbook and execution defines the quarter. Management claimed 'selective order execution to protect margins' — a narrative that sounds disciplined, even prudent. But the delivered result contradicts it: PAT at ₹5.4 crore, the lowest in years, suggests either selection itself failed or acceptable margins are far narrower than management lets on.
Management claims vs. what holds up
Selective order execution protects margins; won't chase unprofitable deals
OverstatedPAT crashed to ₹5.4 Cr (1% margin), lowest in years despite selectivity
Odisha facility on track for Q3 ramp; ALMM-2 inspection Sept 2026
SupportedTool move-in, equipment install underway; inspection planned but not assured
Order book 6.35 GW, worth ₹8,200 Cr; strong forward visibility
SupportedOrder book confirmed at 6.35 GW (~₹8,200 Cr), 132% of current 4.8 GW module capacity
Geopolitical & commodity impacts temporary; expect recovery from Q2
UnverifiedIran war since Feb 20; customer delays, ALMM uncertainty ongoing into Q2; no resolution cited
The execution gap: where Q1 fell short
Three headwinds converged in Q1 to crush sales below capacity: (1) ALMM-1 vs ALMM-2 tariff cliff uncertainty (June 30 cutoff postponed to Jan 1 2027) caused customers to adopt wait-and-watch posture; (2) Geopolitical drag from Iran war (Feb 20) elevated commodity prices, freight costs, and forex volatility, deteriorating project economics and forcing deferrals; (3) No cell manufacturing yet — module-only business is commoditized and margin-starved. Management's 'selective execution' is code for rejecting low-margin orders rather than running the mill. But even with selection, PAT still collapsed to 1%. This implies the module market itself is far worse than prior guidance assumed, or execution failed despite selectivity.
The result: 334 MW sales (vs 579 MW prior-year Q1), ₹511 Cr revenue (vs ₹911 Cr Q1 FY26), and ₹5.4 Cr PAT. The PAT decline (95.5% YoY) dwarfs the revenue decline (44.2% YoY), signaling negative operating leverage — exactly the opposite of what a disciplined, selective operator should deliver. Either margins were already unsustainable, or the order mix shifted sharply unfavourable.
What changed on this call
1. Cell ramp timeline firmed, but inspection becomes a gate. Prior guidance hinted at a faster ramp; now Sept 2026 ALMM-2 inspection is the gate. Expected 80% utilization by Q4 FY27 implies a 3-month ramp from tool move-in (aggressive but not impossible). If the inspection fails or slips, margin recovery slips into FY28 — a material miss vs FY27 6–7% PAT guidance.
2. Order book upgraded; confirmed 6.35 GW vs prior 5.89 GW. New orders secured: ₹138 Cr (Jul 2026, delivery by Dec 2026) + ₹400 Cr (Aug 11, 2026, delivery by Mar 2027). The orderbook is real, but execution timing matters more than size — most of the 6.35 GW has a 12–18 month execution cycle, with large utility projects (70% of orderbook) deferred post-war and ALMM transition. Real demand inflection not expected until FY28.
3. Margin recovery delayed by customer wait-and-watch; geopolitical drag ongoing. ALMM tariff cliff (June 30 → Jan 1) and Iran war (Feb 20) created a perfect storm: projects in deferral mode through May–June. Management acknowledged customer delays into Q2, with no clarity on when clarity arrives.
4. Non-module business (transformer, power electronics, storage) lifted to 15% target by FY28. Currently 4–5% of revenue. Melcon transformer acquisition (mid-Q1) targeting ₹1,000–1,500 Cr revenue in 3–4 years is a strategic shot, but execution risk is high and contribution to FY27 is minimal.
The valuation & street view
The market's verdict on day 1 was sharp: -5.79% decline, delivery 56.5% (volume held). The stock now trades at ₹401.45, a 27% drawdown from its all-time high and below its 20, 50, and 200-day moving averages (at ₹429.9, ₹448.54, ₹425.71 respectively). RSI at 32.7 (oversold lean, but not yet capitulation). Volume increasing — a sign that shorts are piling in or longs are bailing.
Ownership snapshot: Promoters solid at 75.99% (unchanged QoQ). DII holding modest (10.97%, +45 bps QoQ) — mild interest. FII near-zero (0.19%, +16 bps QoQ) — institutional buyers absent. No bulk/block trades reported; no insider selling noted near the highs. This is a retail drawdown, not institution capitulation, which might offer some support if the narrative flips.
Order book ₹8.2K Cr (6.35 GW) confirmed; visibility 12–18 months
Cell ramp (18–20% margins) targets Q3; mechanism credible
Capex ~₹1,000 Cr incurred; ₹3.5K Cr total Phase 1+2 on track
Debt-to-equity 0.99, on track vs 1.0 guidance; leverage manageable
Structural tailwind: 70–80 GW India solar market, 500 GW non-fossil target
Q1 PAT ₹5.4 Cr (1% margin) lowest in years; contradicts FY27 6–7% guidance
Sales execution 334 MW (Q1) vs 875–1,000 MW avg needed for FY27 target
Cell ramp Sept inspection is gate; 3-month ramp to 80% utilization aggressive
Geopolitical drag (Iran war, commodity inflation) ongoing; no resolution timeline
Customer delays into Q2; large utility projects (70% orderbook) deferred to FY28
Module market commoditized; selective execution failed to stem margin collapse
Management credibility gap: promised 'healthy margins', delivered 1% PAT
Cell ramp execution (ALMM-2 inspection Sept, 3-month ramp to 80%)
HighSept inspection is binary gate. If it slips, margin recovery pushes to FY28. If inspection fails, capex loss + guidance miss. 3-month ramp from Q3 leaves no buffer for process issues. Cell margin (18–20%) is the only lever to hit FY27 6–7% PAT guidance; without it, miss is assured.
Margin compression sustained (Q1: 1% PAT, module market commoditized)
HighDespite selective order execution, PAT collapsed 96% YoY. Ratio of PAT decline (95.5%) to revenue decline (44.2%) shows negative operating leverage. Module-only business has no pricing power. If cell ramp slips, margin recovery collapses and leverage works against the company.
Geopolitical drag (Iran war Feb 20, no resolution timeline)
MediumCommodity prices, freight costs, forex volatility elevated. Project economics worse. Already drove customer deferrals in Q1 (334 MW vs 579 MW prior year). No timeline for resolution cited. Drags margin and delays demand into Q2 at earliest.
Customer demand deferred to FY28 (ALMM-1 vs ALMM-2, large utility projects)
Medium70% of orderbook is utility; 18–24 mo project cycles. ALMM tariff cliff (June 30 → Jan 1) caused wait-and-watch in Q1. Large utility DCR projects tendered Dec–present; real execution FY28. FY27 revenue target (₹6K Cr) depends on demand inflection that isn't yet visible.
Debt & capex execution risk (₹3.5K Cr capex, peak debt ₹2.2K–2.4K Cr)
MediumD/E 0.99 on track now, but if Phase 3 ingot/wafer added, leverage rises. Margin shortfall makes debt servicing harder. Capex execution across Phase 1+2+3 simultaneous (civil, equipment, ramp) leaves little room for slippage.
1 · Cell ramp timing & ALMM-2 inspection (Sept 2026)
This is the binary outcome. If inspection clears on schedule, cell production start (Q3) credibly signals margin uplift. If inspection slips or fails, the entire FY27 guidance recovery plan evaporates and margin risk extends into FY28. Watch for management's Sept call commentary on readiness.
2 · Q2 sales execution & customer demand inflection
Q1 delivered 334 MW; FY27 target needs 875–1,000 MW average. Q2 will signal whether ALMM uncertainty and geopolitical drag persist or if customer deferral began to clear. Large utility projects tendered post-war should show signs of revival. Management's commentary on pre-booking and demand visibility is the key read.
3 · Debt & capex burn (₹1,000 Cr incurred; ₹2.5K Cr remaining)
Phase 1+2 capex (₹3.5K Cr total) must complete and ramp simultaneously. Any cost overruns or project delays will stress leverage (D/E 0.99, with peak debt ₹2.2K–2.4K Cr). Watch CFO commentary on burn rate, debt trajectory, and Phase 3 capex plans (ingot/wafer by FY29).
The bottom line
Saatvik Green Energy has a credible long-term thesis — integrated manufacturing (cell + ingot/wafer), structural tailwind from India's solar ambitions, capex on track, order book confirmed. But Q1 execution and profitability collapse have reset credibility and timing expectations. The company is now entirely dependent on cell ramp (Sept inspection, Q3 start) to redeem FY27 guidance. If the ramp executes, margins can recover to high-teens and the long-term story remains intact. If it slips, the stock will face another leg of pain as guidance misses compound.
This is not a step-change quarter — it's a reset. The fundamental opportunity (integrated manufacturing, 70–80 GW market, capex on track) remains. But execution risk is now front and centre, and management credibility has taken a hit. The number to track from here is cell utilization ramp (target 80% by Q4 FY27) and the implied PAT margin recovery it should deliver (target 6–7% for FY27). Without both, the stock will remain under pressure.
Recommendation: Hold, with upside if cell ramp executes, downside if it slips. The stock is down 27% from highs and trading below key averages, but valuation support is limited as long as margin recovery is unproven. Institutional buyers (FII near-zero, DII modest) are absent — a warning signal. The redemption catalyst (cell ramp, Sept inspection) is visible but binary. Risk-reward tilts to hold for now, awaiting cell production proof in Q3 FY27.
Saatvik's integrated manufacturing vision is intact, but execution credibility has eroded. Q1 profitability collapse (₹5.4 Cr PAT, 1% margin) contradicts management's selectivity claims and FY27 guidance (6–7% PAT). Cell ramp (Sept inspection, Q3 start, 80% utilization by Q4) is the only path to recovery, but delivery risk is high. Stock down 27% from ATH; support at key moving averages weak. Hold pending cell ramp proof; watch Sept ALMM-2 inspection closely.
The number to track: Q4 FY27 cell utilization (target 80%) and implied PAT margin recovery from cell manufacturing. Without it, FY27 guidance misses and stock faces another leg of pain.
Saatvik Green Q1 FY27: consolidated PAT sinks 95% YoY to ₹5.4 Cr as revenue nearly halves
PAT -95.49% YoY · revenue -44.19% · margins compressing
₹511.01 Cr
-44.19% YoY
₹5.36 Cr
-95.49% YoY
1.03%
-11.9pp YoY
₹0.43
Saatvik Green Energy's consolidated PAT fell 95.5% YoY to ₹5.4 Cr (from ₹118.8 Cr in Q1 FY26) and 91.1% QoQ (from ₹60.4 Cr in Q4 FY26), on revenue that dropped 44.2% YoY to ₹511.0 Cr and 68.2% QoQ from Q4 FY26's ₹1,607.7 Cr. Basic consolidated EPS fell to ₹0.43 from ₹10.41 a year ago. No confirmed Street consensus for this specific quarter could be located; broader analyst commentary going into FY27 had pencilled in 15-20% full-year PAT growth, a bar this quarter's print runs directly counter to, though three more quarters remain to close the gap.
Q1 FY-2027 vs prior quarters
Management's prior guidance (Q4 FY26 concall) was for "healthy and stable margins for FY27," anchored on in-house solar cell production commencing and industry conditions stabilizing post the recent price war — with operating profit improvement explicitly flagged as an H2 FY27 story tied to backward integration. This quarter's results, reported before that catalyst has kicked in, show margins moving the opposite direction: consolidated NPM compressed to ~1.1% from 12.9% YoY and 3.7% QoQ, and PBT itself was thin at ₹7.4 Cr on ₹511 Cr of revenue. On that basis the quarter reads as a miss against the trajectory management had set out, even allowing for the guided H2 skew.
The stock went into the print at ₹431, down 7.7% over the past month of trading.
What the summary numbers don't show
No exceptional items this quarter vs Q4 FY26's ₹3.95 Cr Monoperc CGU impairment — the decline is purely operational, not one-off driven
Management is confident about the future, projecting healthy and stable margins for FY27, driven by the commencement of in-house solar cell production and an anticipated stabilization of the industry post-war. The company has a robust order book of 5.89 GW (approximately INR 8,000 crores) with an 18-month execution tim
— This quarter: missed
The standalone print tells a materially different story and the divergence is large enough to flag: standalone PAT was ₹6.9 Cr, down only 21.9% YoY on a 11.8% YoY revenue decline to ₹333.2 Cr — a much milder slowdown than the consolidated numbers show. The gap implies the Group's subsidiaries (the 4 GW module manufacturing unit and EPC operations) drove almost all of the consolidated revenue collapse, with their combined contribution falling from roughly ₹537.9 Cr a year ago to about ₹177.8 Cr this quarter, a decline of nearly two-thirds. No standalone management press release was available in the context to cross-check this framing; the filing itself contains only the SEBI-mandated financial statements and auditor review reports, with no separate results commentary from management.
W1
In-house solar cell production commencement (guided from Q2 FY27) and whether it delivers the promised margin stabilization
W2
Execution pace on the ~₹1,146 Cr of fresh orders booked in Aug 2026 against the ₹8,000 Cr / 5.89 GW backlog with 18-month execution
W3
Debt-equity trajectory (guided 1-1.5x) against ₹1,700 Cr of planned FY27 capex, given this quarter's thin ₹7.4 Cr consolidated PBT
Q1 FY26 comparatives in this filing are restated for a retrospective inventory-valuation policy change (FIFO to weighted-average); DB's Q1 FY26 netProfit (₹118.82 Cr) is the pre-restatement figure, filing's restated consol PAT for that quarter is ₹116.60 Cr (~₹2.2 Cr gap, immaterial to this quarter's story). No exceptional items in Q1 FY27, unlike Q4 FY26's ₹3.95 Cr Monoperc CGU impairment. Consolidated PAT (₹5.36 Cr) is profit for the period pre-NCI split, matching DB methodology; owners' share was ₹5.51 Cr against an NCI loss of ₹(0.15) Cr.
Sharp collapse masks intact long-term thesis; cell ramp critical
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Prior FY26 guidance promised 'healthy stable margins' for FY27; Q1 delivered worst profitability on record. Reaffirmed ₹6K Cr ±12% EBITDA target now appears aggressive.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Saatvik's integrated manufacturing thesis is intact and capex on track, but Q1 execution reveals margin vulnerability. PAT collapse to ₹5.4 Cr (1% margin) contradicts FY27 guidance of 6–7% despite management's claim of selective order execution. Cell ramp (Q3) is the redemption path, but delivery risk is high given ongoing geopolitical drag and customer delays.
₹511 Cr
Revenue · −44.2% YoY₹5.4 Cr
Reported PAT · −95.5% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Selective order execution protects margins; won't chase unprofitable deals
OVERSTATEDPAT crashed to ₹5.4 Cr (1% margin), lowest in years despite selectivity
Odisha facility on track for Q3 ramp; ALMM-2 inspection Sept 2026
METTool move-in, equipment install underway; inspection planned but not assured
Order book 6.35 GW, worth ₹8,200 Cr; strong forward visibility
METOrder book confirmed at 6.35 GW (~₹8,200 Cr), 132% of current 4.8 GW module capacity
Geopolitical & commodity impacts temporary; expect recovery from Q2
UnverifiedIran war since Feb 20; customer delays, ALMM uncertainty ongoing into Q2; no resolution cited
Cell manufacturing will drive margin to 'high-double digits'
MISSMechanism sound but delayed; no timeline for when margin uplift hits; Q1 already at 1% PAT
Earnings quality
What changed since the last call
Cell ramp timeline: earlier expectations → Sept 2026 inspection
DowngradePrior call suggested faster ramp; now inspection is gate. Expected 80% utilization by Q4 FY27, not sooner.
Margin recovery delayed by customer wait-and-watch
DowngradeALMM-1 vs ALMM-2 uncertainty, geopolitical drag (Iran war Feb 20) caused customer deferrals into Q2. Q1 margin (1% PAT) far below 6–7% target.
Order book slightly upgraded; confirmed 6.35 GW vs prior 5.89 GW
UpgradeNew orders secured: ₹138 Cr (Jul 2026, delivery by Dec 2026) + ₹400 Cr (Aug 11, 2026, delivery by Mar 2027).
Debt-to-equity on track at 0.99 vs 1.0 guidance
NeutralCurrent debt ₹1,250 Cr; net debt expected to peak ₹2,200–2,400 Cr by FY28. Capex incurred ₹1,000 Cr so far, ~₹3,500 Cr total.
Non-module business contribution target lifted to 15% by FY28
UpgradeCurrently 4–5%; targeting 7–8% this year, 15% by FY28 (Melcon transformer, power electronics, storage, B2C).
The Q&A
Analysts pressed hard on margin compression (down to 1% PAT vs 6–7% guidance) and selectivity claims. CEO acknowledged geopolitical drag, customer delays, ALMM uncertainty, but didn't concede guidance risk. Some evasion on FY28 guidance ('difficult to comment, talk Q3'). Overall: skeptical tone from analysts; management held line on long-term thesis but admitted near-term visibility is challenged.
Margin protection initiatives — Yogesh, NY Associates
AnsweredCell ramp (Sept ALMM-2 inspection, Q3 production). Encapsulant capacity increase to 5 GW (currently 2 GW). Supply chain diversification away from China. Target 'high-double-digit' margins post-cell.
Cell ramp timing & utilization — Manaswini Mukherjee, Oracle
AnsweredRamp-up by end Aug/early Sept. ALMM-2 inspection Sept. Full ramp in 3 months = 80% utilization by Q4 FY27 (2.4 GW cell = ~200 MW/month).
Margin trajectory with integration — Mahesh Kumar, MU Investments
PartialYes. ALMM-2 postponed to Jan 1 due to cell shortage; high demand for domestic ALMM-2 cells. Cell manufacturing = significant EBITDA & bottom-line increase, 'high-double-digits' but specific number withheld.
Q1 EBITDA margin compression root cause — Mahesh Kumar, MU Investments
AnsweredNo cell manufacturing (module-only = crowded). Geopolitical impact (commodity, freight, forex). Customer delays (ALMM-1 vs ALMM-2 uncertainty). Selective order execution to avoid unprofitable deals. Margins should improve Q2 onwards if geopolitical improves & volumes rise.
Order book mix & margin profile — Mahesh Kumar, MU Investments
Answered~70% utility, 30% C&I. ~30% DCR orders. On pricing: C&I ~30% fixed, utility ~30% variable + 70% fixed. DCR margins ~18–20% on cells.
Debt peak & capex guidance — Prakhar Porwal, Ambit Capital
AnsweredCurrent debt ₹1,250 Cr. Net debt expected to peak ₹2,200–2,400 Cr. Phase 1 capex ~₹1,850 Cr (2.4 GW cell + 4 GW module), Phase 2 ~₹1,600–1,700 Cr (3.6 GW cell). Total ~₹3,500 Cr. ₹1,000 Cr incurred so far.
ALMM preponement impact — Prakhar Porwal, Ambit Capital
AnsweredIran war (Feb 20) raised input costs, forcing projects to defer. Force majeure notices issued. Extension expectations softened demand. Tariff cliff from June 30 to July 1 created uncertainty. Projects in wait-and-watch May–June.
Order book to fixed/variable price mix — Prakhar Porwal, Ambit Capital
AnsweredC&I ~30% fixed. Utility ~30% variable, 70% fixed. [Implies utility has better pass-through.]
FY27 full-year guidance — Maria Mittal, individual investor
Answered3.5–4 GW sales. Revenue ~₹6,000 Cr. EBITDA ~12%. PAT margin 6–7%. Non-module business target 7–8% this year, 15% by FY28.
Market position strengthening — Nimish Pandya, NP Investments
AnsweredGovt vision: reduce China dependency. Build integrated ecosystem (module → cell → ingot/wafer). Expand ancillaries (transformers, inverters, storage). Target 50% of project cost vs current 25%. Phase 3: 6 GW ingot/wafer by FY29.
Capacity addition risks — Nimish Pandya, NP Investments
PartialDemand structural (57 GW last year). Electric vehicles, data centers, AI drive growth. Target 70–80 GW market, eventually 100 GW + replacement. Well positioned. Module + cell + backward integration = growth path.
Melcon transformer acquisition — Nimish Pandya, NP Investments
PartialMelcon acquired mid-Q1. Transformer market ₹30K Cr now → ₹55K Cr by 2031. Target 8–10% market share. Planning ₹1,000–1,500 Cr business in 3–4 years. Expansion announcement coming soon.
Order book in INR terms — Preksha, Motilal Oswal
Answered₹8,200 Cr.
DCR order margins — Preksha, Motilal Oswal
AnsweredDCR orders in orderbook assume internal manufacturing. Bought-cell orders are spot, not in book. Internal cell DCR margins: 18–20%.
FY28 guidance — Preksha, Motilal Oswal
DodgedDifficult to comment now; maybe Q3. Geopolitical must improve. Not enough cell capacity. Large utility projects (18–24 mo cycle) tendered Dec–present; real demand FY28 from utility, C&I, KUSUM, retail. FY28 will be 'milestone year'.
Orderbook execution timeline — Nidhin Nath, retail investor
AnsweredOrderbook typically 12–18 mo execution. Retail ~20% of monthly sales, not in orderbook.
Guidance
FY27: 3.5–4 GW sales, ~₹6,000 Cr revenue
MediumReaffirmed but under pressure. Q1 executed only 334 MW sales; need 875–1,000 MW avg per quarter for ₹6K Cr. Cell ramp Q3 is key trigger.
FY27: EBITDA ~12%, PAT 6–7%
LowQ1 delivered 8.33% EBITDA, 1% PAT. To hit 12% EBITDA & 6–7% PAT for year, Q2–Q4 must average ~13% EBITDA, 9–10% PAT. Implied by cell ramp (Sep inspection gate). High execution risk.
Phase 1 + Phase 2: ~₹3,500 Cr total (₹1,850 Cr + ₹1,600–1,700 Cr)
HighIncurred ₹1,000 Cr so far. Aligns with prior FY27 ₹1,700 Cr + FY28 ₹1,800–2,000 Cr guidance. On track.
Risks the call surfaced
Execution risk: cell ramp
HighALMM-2 inspection Sept 2026 is gate. Ramp timeline (3 months to 80% utilization Q4) aggressive. Equipment installation still in progress. Inspection failure or delay derails margin recovery plan.
Margin compression sustained
HighQ1 PAT only ₹5.4 Cr (1% margin) despite 'selective order execution'. Module market commoditized. Geopolitical headwind (commodity, freight, forex) ongoing. FY27 6–7% PAT target may be unachievable without cell margins.
Customer demand uncertainty
MediumALMM-1 vs ALMM-2 tariff cliff (June 30 2026 → Jan 1 2027 postponement) caused significant deferral. Large utility projects (18–24 mo cycle) deferred post-war (Feb 20). Real demand inflection expected only FY28.
Geopolitical & commodity volatility
MediumIran war (Feb 20) elevated commodity prices, logistics costs, forex volatility. Input costs for projects rose; project economics deteriorated. No timeline for resolution cited.
Debt & capex execution risk
MediumCapex ~₹3,500 Cr for Phase 1+2. Current debt ₹1,250 Cr; net debt expected to peak ₹2,200–2,400 Cr. If Phase 3 (ingot/wafer) added, leverage could rise further. Margin shortfall makes debt servicing harder.
Management
Score 6/10. Clear on capex, orderbook, cell roadmap. Acknowledged headwinds (geopolitical, ALMM transition, customer delays). Some hedging on FY28 guidance ('difficult to comment, Q3'). Transparent on selective order approach but weak on reconciling PAT collapse vs margin targets. Cell ramp on track but delayed vs some earlier expectations (Sept inspection gate). Capex ~₹1,000 Cr incurred on track (~₹3,500 Cr total). Orderbook maintained/grown. But Q1 profitability ₹5.4 Cr (1% NPM) far below prior targets; execution quality questioned.
1 · September 2026
ALMM-2 inspection; cell line ramp-up commences
2 · Q3 FY27
Cell production starts; expected 80% utilization by Q4
3 · Q2 FY28
Phase 2 (3.6 GW cell) completion; large utility DCR demand inflection
Cell ramp (Q3) is the redemption path, but delivery risk is high given ongoing geopolitical drag and customer delays.